

Global Recombinant Vaccines Market Report and Forecast 2023-2031

Market Report | 2023-04-28 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Recombinant Vaccine Market Report and Forecast 2023-2031

Global Recombinant Vaccine Market Outlook

The value of the global recombinant vaccine market was USD 13.32 billion in 2022, driven by the technological advancements in vaccine development across the globe. The market value is expected to grow at a CAGR of 11.91% during the forecast period of 2023-2031 to reach a value of USD 36.62 billion by 2031.

Recombinant Vaccine: Introduction

Recombinant vaccines are a type of vaccine that is created by inserting a piece of the pathogen's genetic material, typically DNA or RNA, into a carrier virus or bacteria. This carrier is then used to deliver the genetic material into the body, where it triggers an immune response and the body produces antibodies to fight off the pathogen.

Recombinant vaccines are considered a modern and innovative approach to vaccine development, as they offer several advantages over traditional methods of vaccine production. For example, they can be produced more quickly and with greater precision, and they have a lower risk of contamination or adverse reactions.

Recombinant vaccines have been developed for a variety of diseases, including influenza, hepatitis B, human papillomavirus (HPV), and COVID-19. They are considered a promising area of research for the development of new vaccines, particularly for emerging infectious diseases.

Recombinant Vaccine: Application and Uses

Recombinant vaccines are a type of vaccine that is produced through genetic engineering techniques. These vaccines are made using recombinant DNA technology to produce specific antigens, which are then used to stimulate the immune system and create an immune response against a specific pathogen. Recombinant vaccines have a variety of applications, including:

- Prevention of infectious diseases: Recombinant vaccines are used to prevent infectious diseases such as hepatitis B, human papillomavirus (HPV), and influenza.
- Treatment of cancer: Recombinant vaccines are being developed to treat cancer by stimulating the immune system to target and destroy cancer cells.
- Veterinary medicine: Recombinant vaccines are used to prevent diseases in animals, including livestock and pets.
- Biodefense: Recombinant vaccines are being developed to protect against potential bioterrorism threats, such as anthrax and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

smallpox.

-□Allergies: Recombinant vaccines are used to treat allergies by desensitizing the immune system to specific allergens.

Overall, the use of recombinant vaccines is growing due to their safety, effectiveness, and versatility.

Global Recombinant Vaccine Market Segmentations

Market breakup by Type

-□Live Attenuated

-□Subunit

Market breakup by Disease Indication

-□Hepatitis B

-□Rotavirus

-□Herpes Zoster

-□Meningococcal B

-□Others

Market by Distribution Channel

-□Hospitals

-□Vaccination Centres

Market by End User

-□Paediatrics

-□Adults

-□Veterinary

Market Breakup by Region

North America

-□United States of America

-□Canada

Europe

-□United Kingdom

-□Germany

-□France

-□Italy

-□Others

Asia Pacific

-□China

-□Japan

-□India

-□ASEAN

-□Australia

-□Others

Latin America

-□Brazil

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Argentina
- Mexico
- Others

Middle East and Africa

- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Global Recombinant Vaccine Market Scenario

The global recombinant vaccine market is expected to witness significant growth in the coming years owing to the increasing prevalence of infectious diseases, technological advancements in vaccine development, and the growing demand for vaccines across the world are some of the key factors driving the growth of the market.

Subunit vaccines are expected to hold the largest share of the market due to their lower risk of side effects and better immunogenicity.

Based on technology, the market is divided into conjugate vaccines, inactivated and subunit vaccines, and live attenuated vaccines. Conjugate vaccines are expected to hold the largest share of the market due to their high effectiveness against various diseases

Based on application, the market is divided into infectious diseases, cancer, and others. Infectious diseases are expected to hold the largest share of the market due to the high prevalence of infectious diseases across the world.

Based on end user, the market is divided into pediatrics, adults, and others. Pediatrics are expected to hold the largest share of the market due to the high demand for vaccines in children.

North America is expected to dominate the market due to the high adoption of advanced vaccines and the presence of major players in the region. However, the Asia Pacific region is expected to witness the highest growth in the coming years due to the increasing prevalence of infectious diseases and the growing demand for vaccines in the region.

Key Players in the Global Recombinant Vaccine Market

The report gives an in-depth analysis of the key players involved in the global recombinant vaccine market. The companies included in the market are as follows:

- GSK plc
- Pfizer Inc.
- Sanofi
- Walvax Biotechnology Co., Ltd. (Walvax)
- Dynavax Technologies Corporation
- Merck & Co., Inc.
- Novartis AG
- GC Biopharma
- Bayer AG
- Bharat Biotech
- Sartorius AG
- Serum Institute of India Pvt. Ltd.
- Bio Farma

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Recombinant Vaccine Market Overview
 - 3.1 Global Recombinant Vaccine Market Historical Value (2016-2022)
 - 3.2 Global Recombinant Vaccine Market Forecast Value (2023-2031)
- 4 Global Recombinant Vaccine Market Landscape
 - 4.1 Global Recombinant Vaccine Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Recombinant Vaccine Product Landscape
 - 4.2.1 Analysis by Type
 - 4.2.2 Analysis by Disease Indication
 - 4.2.3 Analysis by Distribution Channel
 - 4.2.4 Analysis by End User
- 5 Global Recombinant Vaccine Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Recombinant Vaccine Market Segmentation
 - 6.1 Global Recombinant Vaccine Market by Type
 - 6.1.1 Market Overview
 - 6.1.2 Live Attenuated
 - 6.1.3 Subunit
 - 6.2 Global Recombinant Vaccine Market by Disease Indication
 - 6.2.1 Market Overview
 - 6.2.2 Hepatitis B
 - 6.2.3 Rotavirus
 - 6.2.4 Herpes Zoster
 - 6.2.5 Meningococcal B
 - 6.2.6 Others
 - 6.3 Global Recombinant Vaccine Market by Distribution Channel
 - 6.3.1 Market Overview
 - 6.3.2 Hospitals
 - 6.3.3 Vaccination Centres

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.4 Global Recombinant Vaccine Market by End User
 - 6.4.1 Market Overview
 - 6.4.2 Paediatrics
 - 6.4.3 Adults
 - 6.4.4 Veterinary
- 6.5 Global Recombinant Vaccine Market by Region
 - 6.5.1 Market Overview
 - 6.5.2 North America
 - 6.5.3 Europe
 - 6.5.4 Asia Pacific
 - 6.5.5 Latin America
 - 6.5.6 Middle East and Africa
- 7 North America Recombinant Vaccine Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Recombinant Vaccine Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Recombinant Vaccine Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASEAN
 - 9.6 Australia
 - 9.7 Others
- 10 Latin America Recombinant Vaccine Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Recombinant Vaccine Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
 - 14.1 Analysis by Funding Instances
 - 14.2 Analysis by Type of Funding
 - 14.3 Analysis by Funding Amount
 - 14.4 Analysis by Leading Players
 - 14.5 Analysis by Leading Investors
 - 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
 - 15.1 Analysis by Partnership Instances
 - 15.2 Analysis by Type of Partnership
 - 15.3 Analysis by Leading Players
 - 15.4 Analysis by Geography
- 16 Regulatory Framework
 - 16.1 Regulatory Overview
 - 16.1.1 US FDA
 - 16.1.2 EU EMA
 - 16.1.3 INDIA CDSCO
 - 16.1.4 JAPAN PMDA
 - 16.1.5 Others
- 17 Supplier Landscape
 - 17.1 GSK plc
 - 17.1.1 Financial Analysis
 - 17.1.2 Product Portfolio
 - 17.1.3 Demographic Reach and Achievements
 - 17.1.4 Mergers and Acquisitions
 - 17.1.5 Certifications
 - 17.2 Pfizer Inc.
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisitions
 - 17.2.5 Certifications
 - 17.3 Sanofi
 - 17.3.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Walvax Biotechnology Co., Ltd. (Walvax)
 - 17.4.1 Financial Analysis
 - 17.4.2 Financial Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisitions
 - 17.4.5 Certifications
- 17.5 Dynavax Technologies Corporation
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Mergers and Acquisitions
 - 17.5.5 Certifications
- 17.6 Merck & Co., Inc.
 - 17.6.1 Financial Analysis
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisitions
 - 17.6.5 Certifications
- 17.7 Novartis AG
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Mergers and Acquisitions
 - 17.7.5 Certifications
- 17.8 GC Biopharma
 - 17.8.1 Financial Analysis
 - 17.8.2 Product Portfolio
 - 17.8.3 Demographic Reach and Achievements
 - 17.8.4 Mergers and Acquisitions
 - 17.8.5 Certifications
- 17.9 Bayer AG
 - 17.9.1 Financial Analysis
 - 17.9.2 Product Portfolio
 - 17.9.3 Demographic Reach and Achievements
 - 17.9.4 Mergers and Acquisitions
 - 17.9.5 Certifications
- 17.10 Bharat Biotech
 - 17.10.1 Financial Analysis
 - 17.10.2 Product Portfolio
 - 17.10.3 Demographic Reach and Achievements
 - 17.10.4 Mergers and Acquisitions
 - 17.10.5 Certifications
- 17.11 Sartorius AG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Serum Institute of India Pvt. Ltd.
 - 17.12.1 Financial Analysis
 - 17.12.2 Product Portfolio
 - 17.12.3 Demographic Reach and Achievements
 - 17.12.4 Mergers and Acquisitions
 - 17.12.5 Certifications
- 17.13 Bio Farma
 - 17.13.1 Financial Analysis
 - 17.13.2 Product Portfolio
 - 17.13.3 Demographic Reach and Achievements
 - 17.13.4 Mergers and Acquisitions
 - 17.13.5 Certifications
- 18 Global Recombinant Vaccine Market - Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors
 - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
 - 20.1 Very Small Companies
 - 20.2 Small Companies
 - 20.3 Mid-Sized Companies
 - 20.4 Large Companies
 - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
 - 21.1 Government Funded
 - 21.2 Private Insurance
 - 21.3 Out-of-Pocket

Global Recombinant Vaccines Market Report and Forecast 2023-2031

Market Report | 2023-04-28 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com